Drug Profile
Exenatide controlled release - Alteogen
Alternative Names: Exenatide-NexP; long-acting Exenatide - AlteogenLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Alteogen
- Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 28 Apr 2017 Discontinued - Preclinical for Type-2 diabetes mellitus in South Korea (Injection)
- 22 Dec 2015 Preclinical trials in Type-2 diabetes mellitus in South Korea (Injection)